The global therapeutic apheresis market is poised for remarkable growth, according to recent forecasts released by FMI. The market, valued at US$ 2,717.9 million in 2023, is anticipated to soar to US$ 5,264.4 million by 2033, representing a robust Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period.
Apheresis, a vital medical procedure involving the separation of blood components, is witnessing escalating demand owing to several key factors driving market expansion. The rising prevalence of diseases requiring therapeutic intervention, coupled with an increased demand for blood components, underscores the market’s growth trajectory. Furthermore, advancements in technology facilitating the development of innovative apheresis techniques, along with favorable reimbursement policies and increased funding for apheresis procedures, serve as primary drivers propelling market growth.
Request A Sample Copy Of This Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5863
“The projected surge in the therapeutic apheresis market is fueled by a confluence of factors, including the rising incidence of blood-related illnesses and supportive government initiatives,” stated FMI. “Additionally, the proliferation of blood donation campaigns and camps, alongside an uptick in blood transfusions, contributes significantly to the expanding demand for apheresis equipment,” he added.
Despite the optimistic outlook, the North American therapeutic apheresis industry faces constraints related to donor availability and histocompatibility. Alarmingly, statistics indicate that only a mere 3% of Americans contribute to blood donation efforts, as reported by the American Red Cross in June 2019. Addressing these challenges will be pivotal in unlocking the region’s full potential in the therapeutic apheresis market.
As the global demand for therapeutic apheresis continues to escalate, FMI remains committed to pioneering innovative solutions and driving advancements in the field to meet the evolving needs of healthcare providers and patients worldwide.
Key Takeaways:
- By 2033, the therapeutic apheresis industry in the United Kingdom is likely to expand, with a CAGR of 4.8%.
- In 2022, the United States developed the therapeutic apheresis business with a share of 28.8%.
- The therapeutic apheresis industry grew considerably to US$ 2,577.9 million in 2022.
- The therapeutic apheresis sector expanded at a CAGR of 4.4% from 2018 to 2022.
- By 2033, China’s therapeutic apheresis industry is projected to develop with a CAGR of 8.3%.
- By 2033, India’s therapeutic apheresis industry is projected to expand with a CAGR of 6.8%.
- Japan’s therapeutic apheresis industry grew significantly, with a 4.2% share in 2022.
- Australia’s therapeutic apheresis industry is likely to expand with a CAGR of 6.1% by 2033.
- Germany’s therapeutic apheresis business grew, with a share of 6.3% in 2022.
- In 2022, based on the technology, centrifugation dominated the market, with a share of 58.3%.
- In 2022, the blood bank segment dominated the market, with a share of 43.5%, based on end users.
Competitors Winning Strategies:
The market has currently demonstrated budding success and is well-established in several locations. As a result of growing government activities, more individuals are becoming aware of the industry under study, fueling its expansion. Strategic partnerships and new product launches by large corporations are also anticipated to fuel market expansion.
Click Here to Request Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-5863
Recent Developments:
- The TORAYMYXIN medical device was introduced to the European market by Toray Medical Co. Ltd. (Japan) in June 2019.
- Baxter International Inc. (United States) introduced the PrisMax system in the US in July 2019.
- In June 2022, Terumo Blood and Cell Technologies announced that the automated red blood cell exchange procedure performed on the company’s Spectra Optia Apheresis System had been selected by the NHS MedTech Funding Mandate (MTFM) programme in NHS England in the United Kingdom to treat sickle cell disease.
- In July 2022, Eliaz Therapeutics and Terumo Blood and Cell Technologies worked together to create and market a breakthrough therapeutic apheresis therapy for acute renal damage (AKI).
Key Players:
- Asahi Kasei Medical Co.
- Haemonetics Corporation
- Miltenyi Biotec
- Cerus Corporation
- Terumo BCT Inc.
- Fresenius Kabi USA
- Terumo Bct
- B. Braun Melsungen AG
- Nikkiso Co. Ltd.
- Medica S.p.A.
- Baxter Healthcare Corporation
- Kawasumi Laboratories Inc.
- Therakos Incorporation
Purchase Now to Access Premium Information: https://www.futuremarketinsights.com/checkout/5863
Key Segments:
By Procedure Types:
- Therapeutic Plasma Exchange (TPE)
- Red Blood Cell Exchange (RBCX)
- Cellular Depletions
By Technology:
- Centrifugation
- Membrane filtration
By Application:
- Hematology
- Neurology
- Nephrology
- Rheumatology
- Oncology
- Others
By End User:
- Hospitals
- Blood banks
- Specialty clinics
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
